ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,562.07
1.04%
US Tech 100
19,318.38
1.62%
Dow Jones
40,384.24
0.24%
Brent Oil
81.635
-0.78%
Bitcoin
67,460.54
-1.02%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Camurus Ab (0RD1)

  7. Camurus Ab (0RD1) News

0RD1

Camurus Ab (0RD1)

Camurus Ab
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0RD1
DateTimeSourceHeadlineSymbolCompany
07/17/20231:40AMPR Newswire (US)Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegalyLSE:0RD1Camurus Ab
07/17/20231:36AMPR Newswire (US)Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegalyLSE:0RD1Camurus Ab
05/23/202311:25PMPR Newswire (US)Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorderLSE:0RD1Camurus Ab
05/23/202311:17PMPR Newswire (US)Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorderLSE:0RD1Camurus Ab
12/15/20215:15PMPR Newswire (US)Braeburn receives new Complete Response Letter for Brixadi in the USLSE:0RD1Camurus Ab
09/16/20215:38AMPR Newswire (US)FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver diseaseLSE:0RD1Camurus Ab
09/16/20215:37AMPR Newswire (US)FDA grants Orphan Drug Designation in the US for CAM2029 for the treatment of polycystic liver diseaseLSE:0RD1Camurus Ab
06/26/202112:09PMPR Newswire (US)Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the USLSE:0RD1Camurus Ab
06/26/202112:02PMPR Newswire (US)Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the USLSE:0RD1Camurus Ab
06/15/20216:12PMPR Newswire (US)Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the USLSE:0RD1Camurus Ab
06/15/20216:05PMPR Newswire (US)Camurus announces Braeburn resubmits New Drug Application for Brixadi™ in the USLSE:0RD1Camurus Ab
05/10/202111:22AMPR Newswire (US)Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...LSE:0RD1Camurus Ab
05/10/202111:21AMPR Newswire (US)Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injecti...LSE:0RD1Camurus Ab
05/03/20212:42AMPR Newswire (US)The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependenceLSE:0RD1Camurus Ab
05/03/20212:40AMPR Newswire (US)The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependenceLSE:0RD1Camurus Ab
03/26/20219:33AMPR Newswire (US)Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependenceLSE:0RD1Camurus Ab
03/26/20219:32AMPR Newswire (US)Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependenceLSE:0RD1Camurus Ab
12/18/20202:27AMPR Newswire (US)Swissmedic approves Buvidal for the treatment of opioid dependenceLSE:0RD1Camurus Ab
12/18/20202:26AMPR Newswire (US)Swissmedic approves Buvidal for the treatment of opioid dependenceLSE:0RD1Camurus Ab
06/24/20208:38AMPR Newswire (US)Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obe...LSE:0RD1Camurus Ab
06/23/202010:39AMPR Newswire (US)Camurus Raises Full Year 2020 Revenue GuidanceLSE:0RD1Camurus Ab
06/23/202010:33AMPR Newswire (US)Camurus Raises Full Year 2020 Revenue GuidanceLSE:0RD1Camurus Ab
06/01/20205:55PMPR Newswire (US)Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the USLSE:0RD1Camurus Ab
06/01/20205:52PMPR Newswire (US)Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the USLSE:0RD1Camurus Ab
05/14/202011:24AMPR Newswire (US)Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid DependenceLSE:0RD1Camurus Ab
05/14/202011:22AMPR Newswire (US)Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid DependenceLSE:0RD1Camurus Ab
05/07/20207:18AMPR Newswire (US)Camurus' Interim Report January-March 2020LSE:0RD1Camurus Ab
05/07/20207:17AMPR Newswire (US)Camurus' Interim Report January-March 2020LSE:0RD1Camurus Ab
04/02/20202:37AMPR Newswire (US)Camurus Announces Strong First Quarter Demand for Buvidal®LSE:0RD1Camurus Ab
04/02/20202:32AMPR Newswire (US)Camurus Announces Strong First Quarter Demand for Buvidal®LSE:0RD1Camurus Ab
 Showing the most relevant articles for your search:LSE:0RD1

Your Recent History

NASDAQ
ACVA
ACV Auctions
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved